I note that:
a) in April 2009 presentation PRR was referring to a 340 patient pivotal study. (see slide 10)
b) subsequnet informal disclosures (Alpha Securities, Bioshares) have hinted that Phase III study may be as small as 60 patients.
c) presentation for tonight indicates that Phase IIb study will be 60 patients. No detail of size of Phase III now being provided.
How big will Phase III be?
I also note that they are now talking up the prospects for an early sale / licensing deal. This would be a good result for PRR shareholders. Might get you 30 cents if the wind is blowing the right way?
- Forums
- ASX - By Stock
- IMM
- patient numbers required for clinical study
patient numbers required for clinical study
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
31.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $450.3M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 5350 | 32.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
28.0¢ | 5098 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 5350 | 0.320 |
4 | 122745 | 0.315 |
8 | 182208 | 0.310 |
8 | 104375 | 0.305 |
17 | 196618 | 0.300 |
Price($) | Vol. | No. |
---|---|---|
0.280 | 5098 | 1 |
0.285 | 1921 | 1 |
0.305 | 21739 | 1 |
0.310 | 10000 | 1 |
0.315 | 26100 | 3 |
Last trade - 09.24am 02/07/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
Day chart unavailable
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online